Navigation Links
Karolinska Development Expands its Life Science Portfolio With BioChromix Pharma
Date:1/14/2010

STOCKHOLM, January 14 /PRNewswire/ -- Karolinska Development AB (publ), and BioChromix AB announced today the formation of BioChromix Pharma AB, a new company working to develop a novel Alzheimer treatment with its unique knowledge of molecular chemistry. Karolinska Development will initially take 28 percent ownership in the new company.

"We are very excited about BioChromix Pharma as they have a novel approach that targets the cause of the disease. This is an important addition to our portfolio", says Conny Bogentoft, CEO of Karolinska Development.

"We have a clear goal - to bring our lead product candidates for Alzheimer's disease to the market. Being part of the Karolinska Development portfolio, will provided direct access to a broad network of key competencies and resources in the pharmaceutical industry which will be of great importance for us in order to succeed", says Peter Asberg, CEO of BioChromix Pharma AB.

About Karolinska Development

Karolinska Development manages one of the largest portfolios of life science companies in Europe.

Using a unique, highly cost efficient business model, the management team guides the commercialization of world class life science innovations, helping to shape the next generation pharma industry. Since 2003, Karolinska Development has built a portfolio of some 40 companies; among the company's projects 12 compounds are undergoing clinical trials. The portfolio also includes a total of 19 potential first in class products. http://www.karolinskadevelopment.com

About BioChromix

BioChromix AB is a company in the life science arena that develops and commercializes products for early stage diagnosis and monitoring of Alzheimer's disease (AD), and identification of biomarkers associated to AD. The Company's methods are based on our novel and patented LCP molecules. The Company also develops an innovative non-invasive live imaging method for AD. http://www.biochromix.com

About BioChromix Pharma

BioChromix Pharma AB is a pharmaceutical company mission is to carry out research and development of novel treatments for neurodegenerative disorders based on its proprietary polymer technology for therapeutics. Current research and development is focused on the treatment of Alzheimer's disease but the prion diseases, Parkinson's disease and other neurodegenerative disorders might also be included in the future. http://www.biochromixpharma.com

For more information please contact:

Conny Bogentoft, CEO, Karolinska Development AB, Cell phone +46-70-668-61-43, info@karolinskadevelopment.com

Peter Asberg, CEO, BioChromix Pharma AB, Cell phone: +46-70-949-17-21, info@biochromixpharma.com

SOURCE Karolinska Development AB (publ), and BioChromix AB


'/>"/>
SOURCE Karolinska Development AB (publ), and BioChromix AB
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation
2. Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial
3. Karolinska Development Closes Fully Subscribed New Share Issue
4. Karolinska Development Strengthens its Management Team With the Appointment of Dr Carl Harald Janson
5. Arena Pharmaceuticals Announces Merck Discontinues Development of Investigational Niacin Receptor Agonist Program for Atherosclerosis
6. Amgens Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines
7. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
8. Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreichs Ataxia Preclinical Development Program
9. Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development
10. BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines
11. Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... ... April 20, 2017 , ... USDM Life Sciences ... life sciences and healthcare industries, is pleased to announce Holger Braemer as ... subsidiary “USDM Europe GmbH” based in Germany. , Braemer is an integral part ...
(Date:4/20/2017)... ... April 20, 2017 , ... ... technology applications, announced today that Chief Executive Officer (CEO) Debbie Gustafson has been ... is the global industry association connecting the electronics manufacturing supply chain. The mission ...
(Date:4/20/2017)... Israel , April 20, 2017  BrainStorm Cell Therapeutics ... technologies for neurodegenerative diseases, announced today that Chaim Lebovits ... Regenerative Medicine,s (ARM) 5 th Annual Cell & Gene ... EDT in Boston . In ... Officer & Chief Operating Officer, will participate in a panel ...
(Date:4/19/2017)... ... April 18, 2017 , ... Alisa Wright, founder and CEO ... from the Purdue College of Pharmacy in Lafayette, Indiana. , The Distinguished Alumni ... achievements in their careers and other scientific endeavors. , Wright began her career ...
Breaking Biology Technology:
(Date:3/23/2017)... , March 23, 2017 The report "Gesture Recognition ... Biometric), Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, the ... a CAGR of 29.63% between 2017 and 2022. ... ... ...
(Date:3/22/2017)... March 21, 2017   Neurotechnology , a ... technologies, today announced the release of the ... provides improved facial recognition using up to 10 ... single computer. The new version uses deep neural-network-based ... and it utilizes a Graphing Processing Unit (GPU) ...
(Date:3/22/2017)... 2017 Vigilant Solutions , a vehicle ... agencies, announced today the appointment of retired FBI special ... safety business development. Mr. Sheridan brings more ... a focus on the aviation transportation sector, to his ... Mr. Sheridan served as the Aviation Liaison Agent Coordinator ...
Breaking Biology News(10 mins):